LLY

908.52

+0.64%↑

UNH

593.89

-0.49%↓

NVO

131.93

+0.67%↑

JNJ

166.62

+1.37%↑

ABBV

196.25

+1.59%↑

LLY

908.52

+0.64%↑

UNH

593.89

-0.49%↓

NVO

131.93

+0.67%↑

JNJ

166.62

+1.37%↑

ABBV

196.25

+1.59%↑

LLY

908.52

+0.64%↑

UNH

593.89

-0.49%↓

NVO

131.93

+0.67%↑

JNJ

166.62

+1.37%↑

ABBV

196.25

+1.59%↑

LLY

908.52

+0.64%↑

UNH

593.89

-0.49%↓

NVO

131.93

+0.67%↑

JNJ

166.62

+1.37%↑

ABBV

196.25

+1.59%↑

LLY

908.52

+0.64%↑

UNH

593.89

-0.49%↓

NVO

131.93

+0.67%↑

JNJ

166.62

+1.37%↑

ABBV

196.25

+1.59%↑

Accueil・Liste d'Actions・Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Fermé

Secteur Soins de santé

252.42 2.45

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

245.29

Max

255.22

Chiffres clés
By Trading Economics
Revenu	49M -17M
Ventes	165M 660M
BPA	0.56
Marge bénéficiaire	-2.56
Employés	2,100
EBITDA	50M 47M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+23.86 upside

Dividendes
By Dow Jones
Prochains Résultats	31 oct. 2024

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-2.5B 33B
Ouverture précédente	249.97
Clôture précédente	252.42

Sentiment de l'Actualité

By Acuity

50%

100 / 365 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

N/A / 280 Support & Résistance

Alnylam Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

8 sept. 2024, 23:42 UTC

Résultats

Syrah Resources: Vidalia AAM Facility Has Ramped Up Operations

8 sept. 2024, 23:41 UTC

Résultats

Syrah Resources: No Natural Graphite Shipments in Half-Year to Chinese Anode Customers Amid Competition, Oversupply

8 sept. 2024, 23:40 UTC

Résultats

Syrah Resources: Half-Year Balama Production and Sales Decreased Compared With Prior Period

8 sept. 2024, 23:37 UTC

Résultats

Syrah Resources: Half-Year Revenue US$19 Mln Vs US$28.4 Mln in Prior Period

8 sept. 2024, 23:37 UTC

Résultats

Syrah Resources: Half-Year Comprehensive Loss US$63.3 Mln Vs US$37.1 Mln Loss in Prior Period

8 sept. 2024, 22:38 UTC

Actualités

Stocks Are Poised to Fall -- Barrons.com

8 sept. 2024, 18:40 UTC

Actualités

Elon Musk's xAI Has Discussed Deal for Share in Future Tesla Revenue, Sources Say -- Update

8 sept. 2024, 15:24 UTC

Actualités

Boeing Reaches Deal With Biggest Union in Effort to Avoid Strike -- WSJ

8 sept. 2024, 13:00 UTC

Actualités

Crypto Plan Creates Potential Conflicts for Trump -- WSJ

8 sept. 2024, 09:00 UTC

Actualités

Nvidia Draws Antitrust Scrutiny as Enforcers Signal Early Interest in AI -- WSJ

8 sept. 2024, 07:30 UTC

Actualités

Biotechs Are in Focus as Congress Looks to Get Tougher on China -- Barrons.com

8 sept. 2024, 01:00 UTC

Actualités

Elon Musk's xAI Has Discussed Deal for Share in Future Tesla Revenue, Sources Say -- WSJ

7 sept. 2024, 17:35 UTC

Actualités

Fed Outlook Remains Uncertain After September Cut -- Barrons.com

7 sept. 2024, 09:30 UTC

Actualités

Jobs Slowdown Frustrates Investors Who Wanted Certainty on the Fed -- Heard on the Street -- WSJ

7 sept. 2024, 08:20 UTC

Market Talk

Financial Services Roundup: Market Talk

7 sept. 2024, 04:05 UTC

Actualités

China's Forex Reserves Rose in August as U.S. Dollar Weakened -- WSJ

6 sept. 2024, 22:41 UTC

Market Talk

KinderCare and StandardAero File for IPOs -- Market Talk

6 sept. 2024, 21:18 UTC

Actualités

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- Update

6 sept. 2024, 21:05 UTC

Actualités

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 4th Update

6 sept. 2024, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6 sept. 2024, 20:39 UTC

Résultats

Update: NIO Stock Caught an Upgrade. Shares Rose. -- Barrons.com

6 sept. 2024, 20:35 UTC

Actualités

Stocks Extend Ugly Week of Losses Amid Economic Uncertainty -- WSJ

6 sept. 2024, 20:34 UTC

Actualités

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 3rd Update

6 sept. 2024, 20:11 UTC

Actualités

Stock Indexes Close Lower After Mixed Jobs Report -- WSJ

6 sept. 2024, 19:51 UTC

Actualités

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- WSJ

6 sept. 2024, 19:16 UTC

Market Talk

U.S. Natural Gas Futures Hold Gains -- Market Talk

6 sept. 2024, 19:14 UTC

Market Talk

Oil Futures Extend Losses on Demand Concerns -- Market Talk

6 sept. 2024, 19:01 UTC

Market Talk

Gold Slips on Prevailing Uncertainty -- Market Talk

6 sept. 2024, 18:27 UTC

Actualités

JPMorgan Plans to Report Customers Who Exploited TikTok 'Glitch' to Authorities -- WSJ

6 sept. 2024, 18:25 UTC

Market Talk

Broadcom Growth Views Conservative Amid AI Investments -- Market Talk

Comparaison

Variation de prix

Alnylam Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

23.86% hausse

Prévisions sur 12 Mois

Moyen 305.67 USD 23.86%

Haut 400 USD

Bas 233 USD

Basé sur 22 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

22 ratings

Achat

Maintien

Vente

Basé sur 22 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

N/A / 280Support & Résistance

All events are bearish.

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

100 / 365Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company's commercial products and pipeline of investigational RNAi therapeutics are focused in four Strategic Therapeutic Areas (STArs): Genetic Medicines, Cardio-Metabolic Diseases, Hepatic Infectious Diseases and CNS/Ocular Diseases. The Company's RNAi-based medicines include ONPATTRO (patisiran), GIVLAARI (givosiran), OXLUMO (lumasiran) and Leqvio (inclisiran). The ONPATTRO (patisiran) is an intravenously administered RNAi therapeutic targeting Transthyretin Amyloidosis (TTR). The GIVLAARI (givosiran) is used to reduce induced liver aminolevulinic acid synthase 1 mRNA, to reduction of toxins associated with attacks and other disease manifestations of Acute Hepatic Porphyria (AHP). The OXLUMO (lumasiran) is an RNAi therapeutic targeting hydroxyacid oxidase 1 for the treatment of Primary Hyperoxaluria Type 1 (PH1). The Leqvio (inclisiran) is used for the treatment of adults with hypercholesterolemia.